目的:观察大剂量地塞米松短程冲击治疗对成人初发免疫性血小板减少症(ITP)的疗效及不良反应。方法:我院初诊ITP患者41例,静脉滴注地塞米松40mg/d,共4d,不进行维持治疗,观察其疗效及不良反应。结果:41例患者均完成4d大剂量地塞米松冲击治疗,完全缓解20例(48.8%),缓解14例(34.1%),未缓解7例(17.1%),初期总有效率(完全缓解+缓解)为82.9%,长期有效率为51.2%(21/41),中位持续有效时间为19(3~42)个月。伴有抗核抗体阳性的患者,其长期有效率明显低于抗核抗体阴性者(P〈0.05)。常见不良反应有高血糖,高血压,低血钾等,在治疗结束后均恢复。结论:大剂量地塞米松短程冲击治疗,并且不进行维持治疗,对成人初发ITP有较好的疗效,治疗相关的不良反应可耐受。
Objective:To evaluate the efficiency and safety of high-dose dexamethasone in the treatment of adult newly diagnosed immune thrombocytopenia(ITP).Method:A total of 41 newly diagnosed ITP patients received dexamethasone 40mg/d intravenously for 4days,without maintenance therapy.The efficiency and adverse reaction are evaluated.Result:All 41 patients finished 4-day high-dose dexamethasone therapy.Twenty cases(48.8%)achieved complete response,14 cases(34.1%)achieved response and 7 cases(17.1%)had no response.The overall initial response rate(complete response+response)was 82.9%.Long-term response rate was 51.2%(21/41).Median time of persistent response was 19 months(range,3 to 42 months).The long-term response of patients with positive antinuclear antibody was significantly lower than that of negative cases(P〈0.05).The most common adverse events included transient hyperglycemia,hypertension and hypokalemia.Conclusion:Single course of high-dose dexamethasone without maintenance therapy demonstrates efficiency in the newly diagnosed ITP and the treatment-related side effects are acceptable and manageable.